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Abstract
Background—The long-term effects of combined antiretroviral therapy (cART) on CD4 
percentage in HIV-infected children are incompletely understood, with evidence from resource-
deprived areas particularly scarce even though most children with HIV live in such settings. We 
sought to describe this relationship.
Methods—Observational longitudinal data from cART-naive children enrolled between 
December 2004 and May 2010 into an HIV care and treatment program in Kinshasa, Democratic 
Republic of Congo were analyzed. To estimate the effect of cART on CD4 percentage while 
accounting for time-dependent confounders affected by prior exposure to cART, a marginal 
structural linear mean model was used.
Results—Seven hundred ninety children were active for 2090 person-years and a median of 31 
months; 619 (78%) initiated cART. At baseline, 405 children (51%) were in HIV clinical stage 3 
or 4; 528 (67%) had advanced or severe immunodeficiency. Compared with no cART, the 
estimated absolute rise in CD4 percentage was 6.8% [95% confidence interval (CI), 4.7% to 8.9%] 
after 6 months of cART, 8.6% (95% CI, 7.0% to 10.2%) after 12 months, and 20.5% (95% CI, 
16.1% to 24.9%) after 60 months. cART-mediated CD4 percentage gains were slowest but greatest 
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among children with baseline CD4 percentage <15. The cumulative incidence of recovery to “not 
significant” World Health Organization age-specific immunodeficiency was lower if cART was 
started when immunodeficiency was severe rather than mild or advanced.
Conclusions—cART increased CD4 percentages among HIV-infected children in a resource-
deprived setting, as previously noted among children in the United States. More gradual and 
protracted recovery in children with lower baseline CD4 percentages supports earlier initiation of 
pediatric cART.
Keywords
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INTRODUCTION
The CD4 cell count and percentage are key markers of HIV disease progression, since 
throughout the course of infection CD4 cells are generally depleted in the absence of 
combined antiretroviral therapy (cART).1,2 In children, initiation of cART at low CD4 levels 
is associated with a reduced likelihood of immune reconstitution3–6 and greater likelihoods 
of growth failure,3,7 clinical progression,7,8 and mortality.9–12 HIV treatment guidelines 
therefore recommend cART initiation at higher CD4 cell counts and percentages.13,14 
Multiple randomized controlled trials15,16 and prospective cohort studies17–19 have 
demonstrated that cART effectively suppresses viral load in children. However, the effect of 
cART on immune reconstitution in pediatric populations, particularly in resource-deprived 
settings, remains incompletely understood.
While randomized trials in the United States20 and Europe15 demonstrated that children 
receiving more potent cART had greater CD4 percentage increases than those receiving 
cART comprised of fewer drugs, the profound survival and clinical progression benefits of 
cART21,22 restricted subsequent investigations of immunological responses to therapy to 
observational contexts. Prior pediatric studies have generally been of short 
duration3,6,7,9–11,18,19,23–32 with limited available sample sizes3,4,7,10,11,19,23–26,28–36 and 
were unable to contrast the effect of cART in comparison to no cART. One study estimated 
the effect of cART versus no cART on CD4 percentage, finding that the mean CD4 
percentage of 1236 US children rose by 2.3% after 1 year of cART compared with no cART, 
with the difference increasing to 4.4% by 5 years.37 Of the studies in low resource 
areas,3,9–11,18,19,23,25–28,38 just 223,38 appraised CD4 responses at more than 2 years after 
cART initiation with none quantifying the effect of cART on immune reconstitution relative 
to no cART.
Global access to cART is expanding,39 including the more than 90%40 of children living 
with HIV infection in areas of the world where poverty and undernutrition are common and 
may affect cART outcomes.41,42 Because cART reduces morbidity and mortality among 
HIV-infected children in resource-deprived settings,43–45 these children may be on cART for 
decades. Hence, understanding immune reconstitution over longer periods of time in this 
population is essential. Further work on responses to cART in this group may also inform 
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the optimal timing of cART initiation in children older than 2 years.14,46–48 Therefore, we 
estimated the effect of cART on mean CD4 percentage in an observational clinical cohort of 
HIV-infected children in the Democratic Republic of Congo (DRC), using marginal 
structural models (MSMs) to account for confounders affected by prior exposure while 
adjusting for time-dependent confounding by indication.
METHODS
Study Population, Measurements, and Follow-up
We used data from a comprehensive family-centered HIV care and treatment program at 2 
sites implementing the same protocol in Kinshasa, DRC: Bomoi Healthcare Center and 
Kalembe Lembe Pediatric Hospital.43,44 The study population was restricted to cART-naive 
children younger than 18 years at baseline with HIV infection confirmed by serology if at 
least 18 months of age and by DNA polymerase chain reaction or HIV viral load otherwise. 
Children initiated HIV care between December 2004 and May 2010. Baseline was defined 
as the date of first CD4 percentage result; as in previous studies,49,50 this allowed children to 
be included despite missing data at program enrollment. Follow-up continued until either the 
date of death or the clinic visit preceding loss to follow-up, transfer of care, or August 2010. 
Children were classified as lost to follow-up if they withdrew from care or were not located 
by 3 tracking attempts in the subsequent months after a missed visit. All children who 
initiated cART contributed no cART person-time before cART initiation.
Laboratory monitoring, diagnosis and treatment of opportunistic infections, and prescription 
of cotrimoxazole prophylaxis and cART were based on national51 and World Health 
Organization (WHO)14,52–54 guidelines. The first-line cART regimen consisted of 
zidovudine or stavudine, lamivudine, and nevirapine or efavirenz and could be initiated at 
any visit after enrollment. Infants younger than 2 years were not always started on therapy 
immediately, as recommended by WHO in 2009,14 because virological diagnostics were 
only intermittently available. Physicians documented clinical data using standardized forms 
during routine visits (scheduled monthly for children receiving cART and quarterly for 
children not receiving cART) and unscheduled visits (for children needing acute care). 
Children not receiving cART were not eligible for treatment according to guidelines. If a 
child died, program personnel collected the date and suspected cause of death. CD4 cell 
count and percentage were assessed biannually at the DRC National AIDS Reference 
Laboratory. HIV viral load was only occasionally available.
Parental written informed consent for the HIV care program was obtained for all children, 
with minors at least 12 years of age additionally providing their written assent. The 
University of North Carolina at Chapel Hill Institutional Review Board and the Ethics 
Committee of the Kinshasa School of Public Health approved the study.
Statistical Analysis
Estimation of the total effect of cART on change in mean CD4 percentage at time t, the 
primary aim of analysis, entails adjustment for factors that are common causes, or 
confounders, of both exposure and outcome. Whereas some confounders are measured at 
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baseline only, others, known as time-varying confounders affected by prior exposure, are 
measured throughout follow-up and are causal intermediates between cART and CD4 
percentage at time t while concurrently common causes of subsequent cART status and CD4 
percentage at time t. Specifying time-varying confounders affected by prior exposure, for 
example CD4 percentage at times prior to t, as time-varying covariates in a standard 
regression model will fail to yield the total effect of cART on change in mean CD4 
percentage at time t because the effects of cART are mediated in part through the time-
varying factors. Therefore, to appropriately estimate the immunological effect of cART in 
the presence of such factors, we used inverse probability weighting.55
Our data set was configured into a one row per person-day structure, with missing covariate 
data carried forward from last measurement. We used 6 logistic regression models to predict 
the outcomes of child and time-specific probabilities of treatment, censoring, and visit 
attendance based on covariate histories (ie, both current and past covariate data). These were 
then multiplied to calculate composite stabilized inverse probability weights. Specifically, 
time and baseline confounders were predictors in the models for the treatment weight 
numerator and denominator, with time-varying confounders affected by prior exposure also 
included in the latter. The censoring weight numerator and denominator models, as well as 
those for the visit attendance weight numerator and denominator, were identical to the 
treatment weight models except for the additional inclusion of time-varying cART as a 
predictor in the 2 censoring models, and both time-varying cART and time since last visit in 
the 2 visit attendance models. The combined weights were then applied in a linear regression 
model with cumulative cART exposure and baseline confounders as independent variables 
and CD4 percentage as the outcome, using only observations with a measured CD4 
percentage result, to estimate the parameters of a linear repeated-measures MSM. To 
account for within-subject correlation induced by weighting and resulting from repeated 
CD4 percentage measurements in individuals, and to yield 95% confidence intervals (CIs) 
based on robust variance, the model was fitted using generalized estimating equations with 
an independent working covariance matrix.49 If children received uninterrupted cART 
during follow-up, plausible in our program because physicians routinely assessed adherence 
and never discontinued treatment for active patients, and assuming correct model 
specification, positivity, and no unmeasured confounding or informative censoring, the 
MSM yields the difference in mean CD4 percentage had all children in the population 
started cART immediately at baseline compared with had they never started cART during 
follow-up. The MSM therefore mimics a randomized controlled trial.
A posited directed acyclic graph56 (see Appendix, Supplemental Digital Content, http://
links.lww.com/QAI/A332) and previous studies informed confounder selection. Age, 
gender, and WHO HIV clinical stage and severity of immunodeficiency were baseline 
confounders, whereas time-varying confounders affected by prior exposure were 
cotrimoxazole prophylaxis, HIV-related symptoms or conditions, and CD4 percentage. Age 
and CD4 levels were used to calculate age-specific severity of immunodeficiency (not 
significant, mild, advanced, or severe), based on WHO guidelines.53 For all children, 
including those for whom follow-up started at first CD4 result rather than HIV care 
initiation, HIV clinical stage (1–4) was that at enrollment because it was assessed only at 
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first visit. A child had HIV-related symptoms or conditions if diagnosed with one or more of 
the following: Kaposi sarcoma, oral or esophageal candidiasis, severe weight loss, 
tuberculosis, fever or diarrhea of 1 month or more, lymphocytic interstitial or Pneumocystis 
jirovecii pneumonia, chronic herpes simplex, oral hairy leukoplakia, cryptococcal 
meningitis, toxoplasma or HIV encephalopathy, or HIV-associated nephropathy. Gender, 
cotrimoxazole, and symptoms or conditions were coded dichotomously, as was cART in 
logistic models. In linear models, cumulative cART exposure was coded into indicators for 
6-month categories, that is, no cART, >0 to 6 months, >6 to 12 months, and so on through a 
maximum of 66 months. Age and time were modeled as restricted cubic splines with 4 knots 
at the fifth, 35th, 65th and 95th percentiles, as was CD4 percentage when a time-varying 
confounder affected by prior exposure. CD4 percentage, which was examined because it is a 
more stable metric than absolute CD4 count in children,57 allowed young children to be 
included, and enabled comparison with a similar US study,37 was expressed as a whole 
number when an outcome in linear models.
Results from unadjusted and adjusted but unweighted linear repeated measures models were 
examined for comparison to elucidate reductions in bias by use of weighted models. To 
estimate the effect of cART on CD4 percentage by baseline categories (CD4 percentage 
<15%, 15%–24%, and ≥25%), models were fitted within those strata. We used the log-rank 
test after constructing Kaplan–Meier plots and Cox proportional hazards regression to assess 
whether time to reaching “not significant” WHO age-specific immunodeficiency (CD4 
percentage >35% for age <1 year, >30% for age ≥1 to <3 years, >25% for age ≥3 to <5 
years, and >500 cells/mm3 for age ≥5 years) differed by degree of immunodeficiency (mild, 
advanced, and severe) at cART initiation. The proportionality of hazards was verified by 
visual inspection of log-negative-log survival estimates. All analyses, including a macro58 to 
generate cumulative incidence curves59 to visually depict time to immunological recovery, 
were completed in SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Characteristics of the 790 children at the start of and during follow-up are presented in Table 
1. At baseline, which corresponded with HIV care initiation for 749 children (94.8%), the 
median age was 5.9 years [interquartile range (IQR), 2.7–9.8] and more than half (405, 
51.3%) had clinically evident stage 3 or 4 HIV disease. As the median CD4 percentage was 
15 (IQR, 9–22), immunodeficiency was either advanced (76, 9.6%) or severe (452, 57.2%) 
in most patients. Cotrimoxazole was initiated by almost all children (726, 91.9%) at first 
visit.
During the 2089.8 person-years accrued, the median duration of follow-up was 31.2 months 
(IQR, 10.3–53.6), and the median number of clinic visits was 30 (IQR, 11–57). The number 
and proportion of patients active in HIV care for at least 12, 24, 36, 48, and 60 months were 
573 (72.5%), 440 (55.7%), 352 (44.6%), 279 (35.3%), and 127 (16.1%), respectively. Eighty 
children (10.1%) died, 76 (9.6%) were lost to follow-up, and 6 (0.8%) transferred to another 
care facility. cART was started by 619 children (78.4%) at a median of 4.0 weeks (IQR, 2.2–
15.3) after baseline. At initiation, the median CD4 percentage was 12 (IQR, 7–18) and 454 
children (73.3%) were severely immunosuppressed. Of the children who initiated cART, 62 
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(10.0%) met the WHO definition of immunological failure (after 24 weeks of cART, 
developing or returning to a CD4 count ≤200 cells/mm3 or percentage ≤10% if older than 2 
to younger than 5 years, or a CD4 count ≤100 cells/mm3 if age older than or equal to 5 
years).14 Children’s durations of cART (including no cART) during follow-up, and the 
number of CD4 percentage measurements during no cART and each of the 6-month 
cumulative cART exposure periods, are depicted in Figure 1. cART was received by 171 
children (21.6%) for zero months, 167 children (21.1%) for >0–12 months, 177 (22.4%) for 
>12–36 months, and 275 (34.8%) for >36 months. Those receiving cART, 110 (17.8%) of 
whom changed regimens because of treatment failure or an adverse event, were followed for 
a median of 31.3 months (IQR, 11.4–52.0) and contributed 1620.9 person-years (77.6% of 
the total) while on cART. Of the 3137 total CD4 percentage measurements, 2485 (79.2%) 
were obtained during receipt of cART.
According to the MSM, cART resulted in a 6.8% (95% CI, 4.7% to 8.9%) absolute rise in 
mean CD4 percentage in the first 6 months and an 8.6% (95% CI, 7.0% to 10.2%) gain at 12 
months, relative to no cART (Table 2, model 1; Fig. 2, panel A). The rate of increase was 
less in subsequent months and years. Not properly accounting for time-varying confounders 
affected by prior exposure yielded attenuated effects (Table 2, models 2–4). For comparison 
to the appropriately adjusted model-based results, we also plotted the observed, unadjusted 
CD4 percentage evolutions for children receiving cART and children not receiving cART 
(Fig. 2, panel F).
The effect of cART on CD4 percentage differed by category of CD4 percentage at baseline 
(Fig. 2, panels B–E). In children with a baseline CD4 percentage ≥25%, CD4 percentage 
rose by almost 10% (95% CI, 7.4% to 12.4%) in the first 12 months, to a mean of 40%, and 
stabilized. In children with a baseline CD4 percentage of 15% to 24%, CD4 percentage 
increased rapidly in the first 12 months, to a mean of 29%, with more gradual increases 
thereafter. Gains were slower in children with a baseline CD4 percentage <15%.
Only 83 of 619 children (13.4%) had “not significant” WHO age-specific immunodeficiency 
at time of cART initiation. There was a reduced hazard of recovery to “not significant” 
immunodeficiency (unadjusted hazard ratio, 0.62; 95% CI, 0.40 to 0.96) and a 
corresponding longer time to recovery (log-rank P = 0.03) if cART was initiated when 
immunodeficiency was severe rather than mild or advanced. In the 82 children who initiated 
cART with either mild or advanced immunodeficiency, the cumulative incidences of 
recovery to “not significant” immunodeficiency at 12, 24, and 36 months were respectively 
28.5%, 36.3%, and 42.7%, whereas the proportions in the 454 children who started cART 
with severe immunodeficiency were 17.5% by 12 months, 26.0% by 24 months, 27.7% by 
36 months, and 29.9% by 48 months (Fig. 3).
DISCUSSION
cART markedly increased the mean CD4 percentage in a cohort of HIV-infected children in 
Kinshasa, DRC compared with no cART, by 8.6% (absolute) at 12 months and 20.5% at 60 
months of cART. Our study provides the first estimate of the effect of cART on CD4 
percentage relative to no cART among antiretroviral-naive children in a resource-deprived 
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setting and just the second estimate of this informative contrast overall.37 This was achieved 
by using inverse probability weighting to account for evident biases. Additionally, our study 
is one of the few providing evidence of sustained CD4 percentage improvements following 
cART initiation in children.44,50
Our findings that cART increased CD4 percentages in children over the short and long term, 
both overall and within baseline CD4 percentage categories, were generally concordant with 
those from the methodologically similar US study.37 That study reported lesser gains 
throughout follow-up (eg, 2.3% and 4.4% at 12 and 60 months, in contrast to 8.6% and 
20.5%). This could be because of the large difference in the baseline CD4 percentage 
distributions of the study populations, as the median baseline CD4 percentage was 
approximately 25% in the US cohort compared with 15% in the Kinshasa cohort. A higher 
baseline CD4 percentage results in lower potentials for gains. The difference was also 
present within strata, and may contribute to the greater and more rapid change we noted 
among children with a baseline CD4 percentage ≥25%.
Among children with a baseline CD4 percentage <15%, the CD4 percentage increases at 12 
and 24 months of cART (4.0% and 10.0%) were close to those noted in the US study (4.4% 
and 8.0%). In these children, the mean CD4 percentage recovered by 42 months to “normal” 
levels (>25%).8,27,37 Although this indicates that recovery is possible for children initiating 
cART with advanced immunodeficiency, CD4 percentages remained below 20% even after 
24 months. The prolonged period of immunodeficiency likely contributes to prolonged 
morbidity and mortality during cART. The decreased probability of immunological 
treatment success following initiation at low CD4 levels revealed in our and prior 
studies,3–6,37 and high mortality rates in children initiating cART at low CD4 
percentages,9–12 provide compelling evidence that pediatric cART should not be delayed 
until CD4 percentages drop below 15%. The newly revised WHO guidelines are in 
accordance with this evidence.14
Not being able to include HIV viral load as a confounder was a limitation (although a prior 
study suggests that not accounting for this factor may have only resulted in nomimal bias50), 
as was the lack of diagnostic capacity in Kinshasa to identify all HIV-related symptoms and 
conditions. The appropriateness of the methodological approach, including accounting for 
the dynamic visit schedule and its potential to influence result validity,60 was supported by 
the dissimilar results from weighted and standard unweighted models. Exposure 
misclassification was minimized through accurate recordkeeping of initiation dates and 
frequent monitoring of adherence. However, because virological monitoring was infrequent 
and drug options were limited in our setting, the possibility exists that some children 
recorded as receiving cART were actually failing therapy, which may have biased our 
estimates downward. Bias resulting from carrying forward CD4 percentage when a result 
was missing, while possible, was likely minimal—assuming that children were on average 
halfway to their next scheduled test when follow-up concluded, 83% of the expected number 
of results was available. The study population probably included a number of HIV slow 
progressors given that some children, whose median CD4 percentage remained stable at 
approximately 25%, were ineligible for cART even after several years (Fig. 2F). Our 
estimates would likely be attenuated relative to those from an otherwise similar population 
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without any slow progressors. Conclusions about immunological responses to cART in very 
young children should be guarded given that just 8% of the population was younger than 1 
year at baseline, although it should be noted that 43% of children, compared with 29% in the 
US study,37 were younger than 5 years at baseline. A strength of our study is that we 
examined immunological recovery by severity of immunodeficiency and not just CD4 
percentage categories.
Our results build upon prior evidence showing the positive immunological impact of 
pediatric cART across CD4 levels and supporting therapy initiation before immune system 
degradation. By contributing unique relevant information on long-term responses in a 
resource-deprived setting, this study widens the breadth of understanding on a relationship 
that is central to the morbidity and mortality outcomes of HIV-infected children. Future 
efforts should focus on pooling data from similar cohorts to more precisely estimate effects 
within immunological subgroups and even longer after cART begins.
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Duration of cART (bars) and number of CD4 percentage measurements during each of the 
6-month periods (lines) in 790 children initiating HIV care between December 2004 and 
May 2010 in Kinshasa, DRC.
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Estimated effect of cART on CD4 percentage from marginal structural model,a overall 
(Panel A) and by category of CD4 percentage at baseline (Panels B–E), and observed 
unadjusted CD4 percentage evolutions among children receiving cART and children not 
receiving cART (Panel F),b 790 children initiating HIV care between December 2004 and 
May 2010 in Kinshasa, DRC. aEstimates are from repeated measures linear models, fit with 
generalized estimating equations, that include time modeled as a restricted cubic spline with 
4 knots. To plot CD4 percentages among children not receiving cART, time was coded 
categorically (6-month periods). As there were no discernible upward or downward trends in 
CD4 percentage over time among children not receiving cART when spline terms were 
included as predictors in the stratum-specific models, it is assumed that the cumulative 
cART exposure parameters represent change from baseline. Error bars represent 95% 
CIs. bThe time scale for children not receiving cART is time since the start of follow-up, 
whereas the time scale for children receiving cART is time since cART initiation. Each box 
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plot depicts the median and IQR, with the error bars marking the 10th and 90th percentiles. 
The most recent CD4 percentage was carried forward to each 6-month cut point.
Edmonds et al. Page 15














Cumulative incidence curves of recovery to “not significant” WHO age-specific 
immunodeficiency, by category of suppression at the start of cART, 536 children initiating 
cART with mild, advanced, or severe immunodeficiency between December 2004 and May 
2010 in Kinshasa, DRC.
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TABLE 1
Characteristics of 790 Children Initiating HIV Care Between December 2004 and May 2010 in Kinshasa, 
DRC
Baseline*
 Median age, years (IQR) 5.9 (2.7–9.8)
 Age [n (%)]
  <1 63 (8.0)
  1–4 277 (35.1)
  5–9 265 (33.5)
  10–17 185 (23.4)
 Female sex [n (%)] 415 (52.5)
 WHO HIV clinical stage [n (%)]
  1 153 (19.4)
  2 232 (29.4)
  3 369 (46.7)
  4 36 (4.6)
 Median CD4 percentage (IQR) 15 (9–22)
 WHO age-specific severity of immunodeficiency [n (%)]
  Not significant 174 (22.0)
  Mild 88 (11.1)
  Advanced 76 (9.6)
  Severe 452 (57.2)
 Started cotrimoxazole at first visit [n (%)] 726 (91.9)
Follow-up (all children)
 Total person-years accrued 2089.8
 Median months of follow-up (IQR) 31.2 (10.3–53.6)
 Median number of program visits (IQR) 30 (11–57)
 Died [n (%)] 80 (10.1)
 Lost to follow-up [n (%)] 76 (9.6)
 Transferred care [n (%)] 6 (0.8)
 Initiated cART 619 (78.4)
 Number of CD4 percentage results 3137
Follow-up (children initiating cART)
 Median weeks of follow-up prior to cART initiation (IQR) 4.0 (2.2–15.3)
 Severe immunodeficiency at cART initiation [n (%)] 454 (73.3)
 Median CD4 percentage at cART initiation (IQR) 12 (7–18)
 cART person-years accrued 1620.9
 Median months on cART (IQR) 31.3 (11.4–52.0)
 Switched cART regimen [n (%)] 110 (17.8)
 Number of CD4 percentage results during cART 2485
*
Baseline (first CD4 percentage result) was not at program enrollment for 41 of 790 children (5.2%). For these 41 children, the median number of 
months between enrollment and first CD4 percentage result was 2.3 (IQR, 1.1–5.3).
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